Literature DB >> 10080

Behavior of transaldolase (EC 2.2.1.2) and transketolase (EC 2.2.1.1) Activities in normal, neoplastic, differentiating, and regenerating liver.

P C Heinrich, H P Morris, G Weber.   

Abstract

The objective of this investigation was to throw light on the biological behavior and metabolic regulation of hepatic enzymes of the nonoxidative branch of the pentose phosphate pathway. The activities of transaldolase (EC 2.2.1.2) and trasketolase (EC 2.2.1.1) Were compared in biological conditions that involve modulation of gene expression such as in starvation, in differentiation, after partial hepatectomy, and in a spectrum of hepatomas of different growth rates. The enzyme activities were determined under optimal kinetic conditions by spectrophotometric methods in the 100,000 X g supernatant fluids prepared from tissue homogenates. The kinetic properties of transaldolase and transketolase were similar in normal liver and in rapidly growing hepatoma 3924A. For transaldolase, apparent Km values of 0.13 mM (normal liver) and 0.17 mM (hepatoma) were observed for erythrose 4-phosphate and of 0.30 to 0.35 mM for fructose 6-phosphate. The pH optima in liver and hepatoma were at approximately 6.9 to 7.2. For the transketolase substrates, ribose 5-phosphate and xylulose 5-phosphate, the apparent Km values were 0.3 and 0.5 mM, respectively, in both liver and hepatoma. A broad pH optimum around 7.6 was observed in both tissues. In organ distribution studies, enzyme activities were measured in liver, intestinal mucosa, thymus, kidney, spleen, brain, adipose tissue, lung, heart, and skeletal muscle. Taking the specific activity of liver as 100%, transaldolase activity was the highest in intestinal mucosa (316%) and in thymus (219%); it was the lowest in heart (53%) and in skeletal muscle (21%). Transketolase activity was highest in kidney (155%) and lowest in heart (26%) and skeletal muscle (23%). Starvation decreased transaldolase and transketolase activities in 6 days to 69 and 74%, respectively, of those of the liver of the normal, fed rat. This was in the same range as the decrease in the protein concentration (66%y. In the liver tumors, transaldolase activity was increased 1.5- to 3.4-fold over the activities observed in normal control rat liver. Transketolase activity showed no relationship to tumor proliferation rate. In the regenerating liver at 24 hr after partial hepatectomy, the activity of both pentose phosphate pathway enzymes was in the same range as that of the sham-operated controls. In differentiation at the postnatal age of 5, 12, 23, and 32 days, hepatic transaldolase activities were 33, 44, 55, and 72%, respectively, of the activities observed in the 60-day-old, adult male rat. During the same period, transketolase activ-ties were 18, 21, 26, and 55% of the activities observed in liver of adult rat. The demonstration of increased transaldolase activity in hepatomas, irrespective of the degree of tumor malignancy, differentiation, or growth rate, suggests that the reprogramming of gene expression in malignant transformation is linked with an increase in the expression of this pentose phosphate pathway enzyme...

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 10080

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  19 in total

1.  The pentose phosphate pathway in regenerating skeletal muscle.

Authors:  K R Wagner; F C Kauffman; S R Max
Journal:  Biochem J       Date:  1978-01-15       Impact factor: 3.857

2.  Evidence for transaldolase activity in the isolated heart supplied with [U-13C3]glycerol.

Authors:  Eunsook S Jin; A Dean Sherry; Craig R Malloy
Journal:  J Biol Chem       Date:  2012-12-12       Impact factor: 5.157

3.  Transaldolase deficiency caused by the homozygous p.R192C mutation of the TALDO1 gene in four Emirati patients with considerable phenotypic variability.

Authors:  Aisha M Al-Shamsi; Salma Ben-Salem; Jozef Hertecant; Fatma Al-Jasmi
Journal:  Eur J Pediatr       Date:  2014-11-12       Impact factor: 3.183

4.  Proteomic analysis of gastric cancer and immunoblot validation of potential biomarkers.

Authors:  Nina Kočevar; Federico Odreman; Alessandro Vindigni; Snježana Frković Grazio; Radovan Komel
Journal:  World J Gastroenterol       Date:  2012-03-21       Impact factor: 5.742

5.  Transaldolase is essential for maintenance of the mitochondrial transmembrane potential and fertility of spermatozoa.

Authors:  Andras Perl; Yueming Qian; Kazim R Chohan; Cynthia R Shirley; Wendy Amidon; Sanjay Banerjee; Frank A Middleton; Karina L Conkrite; Maureen Barcza; Nick Gonchoroff; Susan S Suarez; Katalin Banki
Journal:  Proc Natl Acad Sci U S A       Date:  2006-09-26       Impact factor: 11.205

6.  Deletion of Ser-171 causes inactivation, proteasome-mediated degradation and complete deficiency of human transaldolase.

Authors:  Craig E Grossman; Brian Niland; Christina Stancato; Nanda M Verhoeven; Marjo S Van Der Knaap; Cornelis Jakobs; Lawrence M Brown; Sandor Vajda; Katalin Banki; Andras Perl
Journal:  Biochem J       Date:  2004-09-01       Impact factor: 3.857

Review 7.  The pentose phosphate pathway and cancer.

Authors:  Krushna C Patra; Nissim Hay
Journal:  Trends Biochem Sci       Date:  2014-07-15       Impact factor: 13.807

Review 8.  The molecular determinants of de novo nucleotide biosynthesis in cancer cells.

Authors:  Xuemei Tong; Fangping Zhao; Craig B Thompson
Journal:  Curr Opin Genet Dev       Date:  2009-02-05       Impact factor: 5.578

9.  Transcriptional regulation of metabolism associated with the increased desiccation resistance of the cactophilic Drosophila mojavensis.

Authors:  Luciano M Matzkin; Therese A Markow
Journal:  Genetics       Date:  2009-06-01       Impact factor: 4.562

10.  Elevation of mitochondrial transmembrane potential and reactive oxygen intermediate levels are early events and occur independently from activation of caspases in Fas signaling.

Authors:  K Banki; E Hutter; N J Gonchoroff; A Perl
Journal:  J Immunol       Date:  1999-02-01       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.